Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inspiration’s Hemophilia Pact With Ipsen Gets Surprise Revamp

This article was originally published in Start Up

Executive Summary

Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to buy Inspiration, providing the biotech with the opportunity – and the necessity – to find fresh financing from new backers in the coming months.

You may also be interested in...

In Seeking Focus, Ipsen Turns To Specialty Pharma Model

Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.

Will Novo Nordisk Get Lift From Gut-Brain Axis?

Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.  

Evotec Extends Takeda Pact to Gene Therapy

Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts